This comprehensive case study explores Kymanox’s approach to addressing Commissioning, Qualification, and Validation (CQV) gaps in the client’s in-house expertise for essential GMP project aspects through innovative solutions. Our team of SMEs collaborated closely with stakeholders to implement measurable improvements across facility qualification, validation program development, and long-term operational readiness.
CHALLENGE
SOLUTION
RESULTS
- Address gaps in the Client’s in-house expertise for essential facility validation and regulatory compliance.
- Build a robust validation program to ensure the facility meets all GMP requirements for advanced cell therapy manufacturing.
- Meet a tight project timeline for a fully qualified facility in one (1) year.
- Prepare staff for ongoing operations and future product launches.
- Developed a comprehensive validation program from scratch, including customized procedures and documentation.
- Led the step-by-step implementation of the validation program, encompassing a six-month engineering and validation planning phase.
- Delivered hands-on training to the Client’s team, enabling future independent management of GMP programs.
- Facilitated cross-functional collaboration with operations, engineering, and quality teams to ensure seamless project execution.
- Implemented process validation protocols and facility qualification practices aligned with current regulatory guidelines for CAR T therapies.
- Achieved a fully qualified GMP facility in under six (6) months after construction, meeting the overall one-year project schedule.
- Enabled the client to independently manage their validation program, equipping them with skills for ongoing operations.
- Supported the successful launch of the Manufacturing Center for Advanced Therapeutics (MCAT), celebrated as the first U.S. GMP-compliant facility dedicated to genome-edited CAR T cell therapy products, as highlighted by NCBioTech.
- Positioned the client for operational excellence, regulatory success, and innovation in advanced therapeutic manufacturing.